What is the recommended Exenatide (Byetta / Bydureon) dosage?

Exenatide (Byetta / Bydureon) dosing varies by experience level. Beginners typically start at 5mcg 2x daily, moderate users at 10mcg 2x daily, and aggressive protocols use 2000mcg weekly.

How do you reconstitute Exenatide (Byetta / Bydureon)?

Exenatide (Byetta / Bydureon) comes as a pre-filled device — no reconstitution needed.

What is the half-life of Exenatide (Byetta / Bydureon)?

The half-life of Exenatide (Byetta / Bydureon) is ~2.4 hours (Byetta IR); ~2 weeks sustained release (Bydureon ER). This determines how frequently you need to dose for consistent blood levels.

Exenatide (Byetta / Bydureon)

Weight LossInjectionFDA ApprovedGrade A~2.4 hours (Byetta IR); ~2 weeks sustained release (Bydureon ER) half-life

GLP-1 AgonistType 2 DiabetesBlood Sugar ControlWeight ManagementFDA-Approved

Benefits

First-in-class GLP-1 receptor agonist with extensive long-term safety data

Reduces HbA1c by approximately 0.8-1.0% in clinical trials

Promotes weight loss of 2-3 kg over 30 weeks

Glucose-dependent insulin secretion minimizes hypoglycemia risk

Bydureon weekly formulation offers convenient dosing

Half-Life

~2.4 hours

Route

Injection

Frequency

2x Daily

Vial Sizes

0.25mg, 0.6mg

BAC Water

Pre-filled

Safety Grade

Grade A

Open Exenatide (Byetta / Bydureon) Dosage Calculator

Calculate exact syringe units for your vial and dose

About Exenatide (Byetta / Bydureon)

Exenatide is a synthetic version of exendin-4, a 39-amino-acid peptide originally discovered in the saliva of the Gila monster lizard. It was the first GLP-1 receptor agonist approved for type 2 diabetes (Byetta, FDA approved April 2005). Exenatide shares 53% sequence homology with human GLP-1 but resists degradation by DPP-4 enzyme, giving it a longer duration of action. It enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon, slows gastric emptying, and reduces appetite. Bydureon, an extended-release microsphere formulation approved in 2012, allows once-weekly dosing.

Who Should Consider Exenatide (Byetta / Bydureon)

Adults with type 2 diabetes not achieving adequate glycemic control with metformin, sulfonylurea, or both
Type 2 diabetics seeking a medication that also promotes modest weight loss
Patients who prefer weekly dosing (Bydureon) over daily injections
Adults with type 2 diabetes and cardiovascular risk factors
Patients who cannot tolerate or have contraindications to other oral diabetes agents

How Exenatide (Byetta / Bydureon) Works

Exenatide binds to and activates the GLP-1 receptor, a G-protein-coupled receptor expressed on pancreatic beta cells, the GI tract, and the central nervous system. In the pancreas, it enhances glucose-dependent insulin secretion and suppresses inappropriately elevated glucagon output. In the gut, it slows gastric emptying, which moderates postprandial glucose spikes and contributes to satiety. In the brain, it acts on hypothalamic appetite centers to reduce food intake. Unlike native GLP-1 (half-life ~2 minutes), exenatide resists DPP-4 enzymatic cleavage due to its exendin-4 backbone, extending its functional half-life to 2.4 hours. The Bydureon formulation uses poly(D,L-lactide-co-glycolide) microspheres to create a sustained-release depot, maintaining therapeutic plasma levels for a full week.

What to Expect

Weeks 1-4

5mcg twice daily

Initial titration phase. Nausea is most common during this period and typically subsides. Mild appetite reduction begins. Fasting glucose starts to improve. Body adjusts to GLP-1 receptor activation.

Weeks 5-12

10mcg twice daily

Full Byetta dose reached. HbA1c begins to drop measurably. Weight loss of 1-2 kg is typical. GI side effects diminish for most patients. Postprandial glucose excursions are noticeably blunted.

Weeks 13-30

Steady-state glycemic improvement. Phase 3 trials showed HbA1c reductions of 0.8-1.0% and weight loss of 2-3 kg by week 30. Appetite suppression stabilizes. Blood pressure may modestly decrease.

Weeks 30-52

Sustained glycemic and weight benefits. Open-label extension data showed continued HbA1c improvement and progressive weight loss up to 5 kg over 82 weeks. Beta-cell function markers improve.

Year 1+

Long-term maintenance of glycemic control. Two-year data showed sustained HbA1c reduction, ongoing weight loss, and improvements in hepatic biomarkers (AST, ALT). Regular monitoring of renal function and pancreatic enzymes recommended.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	5mcg	2x Daily
Moderate	10mcg	2x Daily
Aggressive	2mg	Weekly

Note: First GLP-1 receptor agonist approved by the FDA (2005). Byetta: 5mcg or 10mcg twice daily via pre-filled pen. Bydureon: 2mg once weekly extended-release microsphere suspension. Titrate Byetta from 5mcg to 10mcg after 1 month. Carries a black box warning for medullary thyroid carcinoma risk.

How to Inject Exenatide (Byetta / Bydureon)

Byetta: Inject subcutaneously within 60 minutes before the two main meals of the day (at least 6 hours apart). Rotate injection sites (abdomen, thigh, upper arm). Start at 5mcg twice daily for at least 1 month, then increase to 10mcg twice daily if tolerated. Bydureon: Inject 2mg subcutaneously once weekly, any time of day, with or without meals. Same day each week. Reconstitute the microsphere suspension immediately before injection.

Cycling Protocol

On Period

52 weeks

Off Period

0 weeks

Exenatide is prescribed as continuous long-term therapy for type 2 diabetes management. No cycling is needed. Discontinuation should be discussed with a prescribing physician, as glycemic control may deteriorate.

Pharmacokinetics

Half-Life

2.4h

Bioavailability

SC: ~65-75% (estimated from clinical PK modeling)

Tmax

~2.1 hours (Byetta IR); 2-7 weeks to steady state (Bydureon ER)

Data Confidence

high

Source: Byetta FDA Prescribing Information, Section 12.3 — mean terminal half-life 2.4 hours

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Nausea (most common, typically decreases over time), vomiting, diarrhea. Injection site reactions with Bydureon (subcutaneous nodules). Rare: acute pancreatitis, renal impairment. Black box warning for thyroid C-cell tumors including medullary thyroid carcinoma (observed in rodent studies).

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC) — black box warning
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
History of severe hypersensitivity to exenatide or any product components
Severe renal impairment (CrCl <30 mL/min) or end-stage renal disease
History of pancreatitis
Pregnancy or breastfeeding — not studied; potential fetal harm based on animal data
Severe gastrointestinal disease (e.g., gastroparesis)
Type 1 diabetes or diabetic ketoacidosis — not indicated for these conditions

Drug Interactions

Insulin and sulfonylureas — increased risk of hypoglycemia; dose reduction of the sulfonylurea may be needed
Oral medications — delayed gastric emptying may affect absorption rate; take antibiotics and oral contraceptives at least 1 hour before exenatide injection
Warfarin — case reports of increased INR; monitor coagulation parameters closely when initiating or changing exenatide dose
Acetaminophen — Cmax decreased and Tmax delayed by approximately 2 hours when co-administered; clinical significance is limited
Digoxin — Cmax reduced by 17% and Tmax delayed by 2.5 hours; monitor digoxin levels
Lovastatin — AUC and Cmax decreased by approximately 40% and 28% respectively; consider timing of statin administration